BENNETT C FRANK

SEC source: 0000874015-20-000164 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,947

Underlying: Common Stock · 0 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-20-000164 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,476

F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00-$51.70, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-20-000164 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,529

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020.

SEC source: 0000874015-20-000144 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-20-000144 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,476

F1 · shares: Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.50-$46.90, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.

SEC source: 0000874015-20-000144 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,476

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020.

SEC source: 0000874015-20-000119 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,476

F1 · kind: Reporting 112 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on August 31, 2020. These 112 shares may not be sold until February 28, 2021.

SEC source: 0000874015-20-000083 · primary_doc.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 15,000 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-20-000083 · primary_doc.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,364

F1 · shares: Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.75 to $59.80, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.

SEC source: 0000874015-20-000083 · primary_doc.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,364

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option pursuant to a Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 14, 2020.

SEC source: 0000874015-20-000048 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,364

F1 · kind: Reporting 169 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 29, 2020. These 169 shares may not be sold until August 30, 2020.

SEC source: 0000874015-20-000024 · edgar.xml · derivative · entry 4

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,549

Underlying: Common Stock · 11,711 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as determined by Ionis.

SEC source: 0000874015-20-000024 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,612

Underlying: Common Stock · 21,612 shares

Expires not disclosed

F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as determined by Ionis.

SEC source: 0000874015-20-000024 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,195

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-20-000024 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,357

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-20-000006 · edgar.xml · derivative · entry 1

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,626

Underlying: Common Stock · 48,626 shares

Expires 2027-01-01

F1 · derivative.exercise_date: Grant on 01/02/2020 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2020. 25% of the shares subject to the option will vest and become exercisable on 01/02/2021. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-19-000083 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,646

F1 · kind: Reporting 118 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2019. These 118 shares may not be sold until January 2, 2020.

F1 · shares: Reporting 118 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2019. These 118 shares may not be sold until January 2, 2020.

SEC source: 0000874015-19-000032 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,013 shares

Expires 2020-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000032 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,528

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F1 · price: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

SEC source: 0000874015-19-000032 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

SEC source: 0000874015-19-000030 · edgar.xml · derivative · entry 4

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,463

Underlying: Common Stock · 7,822 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-19-000030 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,797

Underlying: Common Stock · 20,797 shares

Expires not disclosed

F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-19-000030 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,400

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

SEC source: 0000874015-19-000030 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-19-000004 · edgar.xml · derivative · entry 2

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,800

Underlying: Common Stock · 46,800 shares

Expires 2026-01-01

F2 · derivative.exercise_date: Grant of 01/02/2019 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019.

SEC source: 0000874015-19-000004 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,524

F1 · kind: Reporting of shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019.

F1 · shares: Reporting of shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019.

SEC source: 0000874015-18-000124 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,013

Underlying: Common Stock · 12,500 shares

Expires 2020-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-18-000124 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,396

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.35 to $49.75, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-18-000124 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,896

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

SEC source: 0000874015-18-000107 · edgar.xml · derivative · entry 6

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,513

Underlying: Common Stock · 12,487 shares

Expires 2020-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-18-000107 · edgar.xml · derivative · entry 5

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13 shares

Expires 2019-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-18-000107 · edgar.xml · nonDerivative · entry 4

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,396

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

SEC source: 0000874015-18-000107 · edgar.xml · nonDerivative · entry 3

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,883

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

SEC source: 0000874015-18-000107 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,396

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

SEC source: 0000874015-18-000107 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,409

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

SEC source: 0000874015-18-000097 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,396

F1 · kind: Reporting 282 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2018. These 282 shares may not be sold until January 2, 2019.

F1 · shares: Reporting 282 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2018. These 282 shares may not be sold until January 2, 2019.

SEC source: 0000874015-18-000064 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13

Underlying: Common Stock · 12,500 shares

Expires 2019-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-18-000064 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,114

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

SEC source: 0000874015-18-000064 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,614

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

SEC source: 0000874015-18-000037 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,513

Underlying: Common Stock · 12,500 shares

Expires 2019-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-18-000037 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,114

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.32 to $52.68, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-18-000037 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,614

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017.

SEC source: 0000874015-18-000019 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,114

F3 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.760 to $51.761, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

SEC source: 0000874015-18-000019 · edgar.xml · derivative · entry 4

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,148

Underlying: Common Stock · 6,663 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F1 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-18-000019 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,137

Underlying: Common Stock · 12,137 shares

Expires not disclosed

F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F6 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.

F1 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F1 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-18-000019 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,810

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F2 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-18-000002 · edgar.xml · derivative · entry 2

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,619

Underlying: Common Stock · 54,619 shares

Expires 2025-01-01

F2 · derivative.exercise_date: Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 13,655 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.

SEC source: 0000874015-18-000002 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,147

F1 · kind: Reporting 106 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 106 shares may not be sold until July 2, 2018.

F1 · shares: Reporting 106 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 106 shares may not be sold until July 2, 2018.

SEC source: 0000874015-17-000064 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,250 shares

Expires 2018-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-17-000064 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,041

F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2017.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 1/27/2017.